This study evaluates the impact of preoperative albumin-to-fibrinogen ratio (AFR) and albumin-to-D-II aggregates ratio (ADR) on LOS in patients with locally advanced ESCC undergoing neoadjuvant therapy. The gene discussed is ALB; the disease is esophageal squamous cell carcinoma.